If we consider the results obtained in human medicine in lung carcinomas in which the percentage of 3+ IHC cases for HER2 varies from 6 to 35%, our study and that of Yoshimoto and coauthors present comparable values [12,22]. The gene discussed is ERBB2; the disease is lung carcinoma.